Track topics on Twitter Track topics that are important to you
Opicinumab, a novel remyelinating agent, didn't show a 'linear dose response' of clinical improvement across 4 treatment groups. But it may still have potential for certain patients, say experts.
Medscape Medical News
Original Article: SYNERGY: Anti-LINGO Agent Misses Primary Endpoint in MSNEXT ARTICLE